Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma

New England Journal of Medicine

Volumn 375, Issue 15, 2016, Pages 1501-1502

  Hari, Parameswaran ^a   Raj, Renju V ^a   Olteanu, Horatiu ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CD2 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD56 ANTIGEN; CISPLATIN; DARATUMUMAB; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; OXALIPLATIN; ANTINEOPLASTIC AGENT; CD38 PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY;

ADULT; BONE LESION; BRAIN DAMAGE; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; CONSOLIDATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; NATURAL KILLER CELL; OFF LABEL DRUG USE; PRIORITY JOURNAL; SPINAL CORD LESION; T CELL LYMPHOMA; TAIWANESE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS TITRATION; ANTAGONISTS AND INHIBITORS; ISOLATION AND PURIFICATION; LYMPHOMA, EXTRANODAL NK-T-CELL; MIDDLE AGED; RECURRENT DISEASE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECURRENCE;

EID: 84991282075     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1605684     Document Type: Letter

References (5)

1. Ishida F, Ko YH, Kim WS, et al. Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci 2012; 103: 1079-83.
2. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015; 373: 1207-19.
3. Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012; 120: 2973-80.
4. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood 2013; 121: 4997-5005.
5. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-8.